Literature DB >> 25446621

Relationship of glycated hemoglobin A1c, coronary artery calcification and insulin resistance in males without diabetes.

Chan-Hee Jung1, Eun-Jung Rhee2, Kyu-Jin Kim1, Bo-Yeon Kim1, Se Eun Park2, Yoosoo Chang3, Seungho Ryu3, Cheol-Young Park2, Ji-Oh Mok1, Ki-Won Oh2, Chul-Hee Kim1, Sung-Woo Park2, Sung-Koo Kang1, Won-Young Lee4.   

Abstract

BACKGROUND AND AIMS: We undertook this study to compare the prevalence of coronary artery calcification (CAC) across glycated hemoglobin A1c (HbA1c) in nondiabetic males and to evaluate the impact of insulin resistance on CAC in relation to HbA1c levels.
METHODS: A cross-sectional study was performed in 18,504 adult males without diabetes mellitus and cardiovascular disease (CVD). CAC scores were measured by multidetector computed tomography; CAC was defined as a CAC score >0. Insulin resistance was estimated using the homeostasis model assessment of insulin resistance (HOMA-IR). Subjects were grouped by HbA1c quartile (≤5.4%, 5.4-5.6%, 5.7%, 5.8-6.4%).
RESULTS: Thirteen percent of subjects (n = 2,406) had a CAC score >0. The prevalence of CAC increased with increasing HbA1c quartile (9.4%, 11.1%, 14.1%, 17.3%). Crude odds ratios (ORs) for CAC were 1.2, 1.58 and 2.01 for the HbA1c quartiles 2, 3, and 4 when compared with the first quartile. Mean HOMA-IR levels were different among HbA1C categories and CAC status. HOMA-IR levels were higher in subjects with CAC than in those without, except in the third HbA1c quartile. Stratification by HbA1c showed a significant association between CAC and insulin resistance only in the first (OR 1.67) and fourth (OR 1.33) HbA1c quartile. After adjustment for CV risk factors, insulin resistance remained an independent predictor of CAC only in the first HbA1c quartile.
CONCLUSIONS: Our study demonstrated that not only glucose status represented by HbA1c but also insulin resistance might be associated with CAC in non-diabetic Korean men. The magnitude of association of CAC with insulin resistance was greater in the lowest HbA1c quartile group.
Copyright © 2015 IMSS. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Coronary artery calcification; Glycosylated hemoglobin; Insulin resistance

Mesh:

Substances:

Year:  2014        PMID: 25446621     DOI: 10.1016/j.arcmed.2014.11.011

Source DB:  PubMed          Journal:  Arch Med Res        ISSN: 0188-4409            Impact factor:   2.235


  5 in total

Review 1.  Pathology of Human Coronary and Carotid Artery Atherosclerosis and Vascular Calcification in Diabetes Mellitus.

Authors:  Kazuyuki Yahagi; Frank D Kolodgie; Christoph Lutter; Hiroyoshi Mori; Maria E Romero; Aloke V Finn; Renu Virmani
Journal:  Arterioscler Thromb Vasc Biol       Date:  2016-12-01       Impact factor: 8.311

2.  The association between glycosylated haemoglobin and newly diagnosed hypertension in a non-diabetic Sudanese population: a cross-sectional study.

Authors:  Saeed M Omar; Imad R Musa; Omer Abdelbagi; Manal E Sharif; Ishag Adam
Journal:  BMC Cardiovasc Disord       Date:  2022-05-10       Impact factor: 2.174

3.  Association between metformin use and below-the-knee arterial calcification score in type 2 diabetic patients.

Authors:  Aurélien Mary; Agnes Hartemann; Sophie Liabeuf; Carole Elodie Aubert; Salim Kemel; Joe Elie Salem; Philippe Cluzel; Aurélie Lenglet; Ziad A Massy; Jean-Daniel Lalau; Romuald Mentaverri; Olivier Bourron; Saïd Kamel
Journal:  Cardiovasc Diabetol       Date:  2017-02-15       Impact factor: 9.951

4.  Glycated Hemoglobin is a Better Predictor than Fasting Glucose for Cardiometabolic Risk in Non-diabetic Korean Women.

Authors:  So Ra Yoon; Jae Hyang Lee; Ga Yoon Na; Yu Jeong Seo; Seongho Han; Min-Jeong Shin; Oh Yoen Kim
Journal:  Clin Nutr Res       Date:  2015-04-24

5.  Elevated glycosylated hemoglobin levels and their interactive effects on hypertension risk in nondiabetic Chinese population: a cross-sectional survey.

Authors:  Jian Song; Nana Wei; Yingying Zhao; Yuhong Jiang; Xuesen Wu; Huaiquan Gao
Journal:  BMC Cardiovasc Disord       Date:  2020-05-12       Impact factor: 2.298

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.